Pelthos Q2 FY26 net loss narrows to $23.42 million; net product revenue climbs 45% to $15.4 million

Reuters2026/08/13 11:10

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Pelthos posted a GAAP net loss of USD 23.4 million, narrowing from USD 25.1 million in the prior quarter.
Net product revenue rose 45% quarter-over-quarter to USD 15.4 million, driven by Zelsuvmi.
Adjusted EBITDA loss narrowed to USD 5.7 million under non-GAAP measures, from USD 8 million in the prior quarter.
Zelsuvmi units dispensed climbed 48% quarter-over-quarter to 11,925, written by 4,571 unique prescribers.
Management cited July dispensing of more than 4,200 units, targeting Xepi commercialization in Q1 2027, Xeglyze in Q3 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pelthos Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608130710PRIMZONEFULLFEED9809219) on August 13, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Pelthos Q2 FY26 net loss narrows to $23.42 million; net product revenue climbs 45% to $15.4 million

You may also like

Crypto prices